echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > These 23 drug companies are on! LiZhu, Colum... Selected as a national technology innovation demonstration enterprise.

    These 23 drug companies are on! LiZhu, Colum... Selected as a national technology innovation demonstration enterprise.

    • Last Update: 2020-10-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Through the 2020 review and evaluation of the national list of technological innovation demonstration pharmaceutical enterprises Lizhu Group: adhere to the "talent strategy, product strategy, market strategy" three strategies Lizhu Group performance (units: 100 million yuan) Lizhu Group to pharmaceutical product research and development, production and sales of the main industry, products covering preparation products, apid materials and intermediates and diagnostic reagents and equipment.
    2019 revenue of 9.385 billion yuan, net profit of 1.303 billion yuan, in the first half of this year, revenue exceeded 5 billion yuan, net profit reached 1.005 billion yuan.
    Lizhu Group said that the company adheres to the "talent strategy, product strategy, market strategy" three strategies, adhering to the patient's life quality first mission, to be a leader in the pharmaceutical industry as the vision, and continuously improve the control efficiency and governance level, accelerate the steady progress of research and development, continue to strengthen marketing management, achieved steady growth in performance.
    first half of this year, Lizhu Group spent 350 million yuan on research and development, an increase of 1.63 percent year-on-year, accounting for 6.87 percent of total revenue.
    Among them, in chemical and traditional Chinese medicine preparations, continue to focus on innovative drugs and high-barrier complex preparations, continue to focus on cutting-edge technology and clinically unseeded needs, accelerate innovation and upgrading, optimize the matrix research and development management structure, from the progress, quality of two dimensions of project control, medical team, clinical team, KA Departments closely integrated, the core focus in research product development progress significantly accelerated, the establishment of clinical research quality management system (cQMS), clinical research process optimization and integration, according to the progress of research varieties, carry out special pharmaceutical inspection and clinical inspection, effectively avoid the scientific research quality system and the potential risks in the research and development process.
    in biopharmacerie, Lizhu single resistance from the focus of the project, improve the team and optimize the platform three aspects to focus on the promotion.
    , Lizhu Group announced plans to spin off Lizhu Reagent to list on A-shares.
    Lizhu Group pointed out that the spin-off will help Lizhu reagents to broaden financing channels, further establish brand influence in the field of IVD (in-body diagnostics), improve operational efficiency and profitability, but also help the Group to further focus on its main business, and actively carry out innovative drugs and high-barrier generic drug research and development.
    Koren Pharmaceuticals: To build into a global competitiveness of innovative-oriented international pharmaceutical company Colum Pharmaceuticals performance (units: 100 million yuan) Colum Pharmaceuticals as a leading enterprise in large infusions, the main products cover analgesic anesthesia, breathing, cardiovascular, anti-tumor and so on.
    as of June 30, 2020, the company has 590 varieties of a total of 1010 specifications of pharmaceutical products, of which 129 varieties of a total of 302 specifications of infusion products, 401 varieties of a total of 646 specifications of other dosage forms of pharmaceutical products, 60 varieties of a total of 62 specifications of raw materials.
    and 12 varieties of antibiotic intermediates, 4 varieties of a total of 7 specifications of medical equipment.
    revenue exceeded 17 billion yuan in 2019, with a net profit of 938 million yuan, and in the first half of this year, the company's revenue of 7.231 billion yuan and net profit of 203 million yuan were affected by factors such as the outbreak of new crown pneumonia.
    has been Colum Pharmaceuticals vigorously promote research and development innovation, has invested more than 6 billion yuan.
    2019, the company invested more than 1.3 billion yuan in research and development, up 21.24% YoY, accounting for 7.66% of revenue.
    first half of this year, the company invested 769 million yuan in research and development, up 15.48 percent year-on-year, accounting for 10.37 percent of revenue.
    this year, 12 products have been approved for listing, 11 declared production.
    since 2017, 49 (first imitation/first 20) have been approved for listing, of which 24 (34 specifications) have been over-evaluated (11 are the first), 10 varieties have been approved according to the newly registered classification, and 13 varieties of innovative drugs have been approved for clinical research.
    It is understood that Colum Pharmaceuticals has five national innovation platforms, the establishment of a national postdoctoral research workstation, quickly completed with international standards of generic drugs, innovative drugs and translational medicine three functional systems, successfully built to Chengdu Research Institute as the core, Suzhou, Tianjin, New Jersey Research Branch as a branch of intensive research and development system.
    company has won a total of 13 "national key new products" title, has undertaken 12 "major new drug creation" science and technology major projects, a national science and technology support plan and a national science and technology foreign aid projects.
    As of June 30, 2020, Colum Pharmaceuticals has applied for 3,939 patents at home and abroad, obtained 2,532 patents, in the field of tumors, bacterial infections, intestinal nutrition, cardiovascular and other diseases have launched more than 500 major drug development, innovative patents overseas licensing, marking Colum's drug research and development has entered the "imitation to promote innovation, innovation to drive the future", and successfully entered the international market virtuous circle.
    Koren Pharmaceuticals said in its annual report that it will strive to build the company into an innovative, globally competitive international pharmaceutical company through a deep focus and efficient operation of the two core areas of generics and innovative pharmaceuticals.
    , Colum Pharmaceuticals announced plans to spin off its subsidiary, Yili Chuanning Bio to GEM.
    Kangyuan Pharmaceutical Industry: adhere to the modernization of Traditional Chinese medicine as the core, layout of chemical medicine, biological medicine Kangyuan Pharmaceutical industry performance (unit: 100 million yuan) Kangyuan Pharmaceutical Industry is a leading enterprise to science and technology, research and development to promote the modernization of Traditional Chinese medicine, the main product line focuses on anti-infection, gynecology, cardiovascular, orthopaedic and other areas of Chinese medicine advantages.
    2019 operating income of 4,566 million yuan, net profit of 507 million yuan, an increase of more than 10% year-on-year.
    first half of this year, affected by the new crown outbreak, revenue of 1.547 billion yuan, net profit of 144 million yuan.
    As of the first half of this year, the company has obtained a total of 204 pharmaceutical production approvals (including 44 subsidiary production batches), of which 42 drugs are exclusive varieties of Chinese medicine, a total of 4 varieties of Chinese medicine protection;
    Kangyuan Pharmaceutical Industry adheres to the core development path of modernization of Chinese medicine, taking into account the layout of chemical drugs, biological drug research and development, research and development investment over the years accounted for about 10% of operating income, is the most exclusive innovative varieties, the most exclusive medical insurance varieties, the most exclusive base drug species of one of the Chinese medicine enterprises.
    , the company further strengthened research and development of new drugs, research and development costs of nearly 200 million yuan.
    obtained a rib pain relief gel 1 Chinese medicine registration approval, apricot anti-whey particles, lumen through oral solution, thermotoxine particles 3 Chinese medicine clinical trial notice, authorized the invention of 26 patents.
    In addition, continue to promote medical insurance or the key varieties of the drug after the market in-depth study, orderly development of jin Zhen oral solution, apricot cough particles, hot toxic ning injections and other major varieties of evidence-based medical clinical research, at the same time, in-depth Ginkgo dicone Basic research, such as the efficacy components and mechanism of action of varieties such as esters glutamide injections and cinnamon capsules, provides strong support for the academic promotion of listed varieties and the rational clinical use of drugs, and actively promotes the pre-research preparations for the follow-up clinical trial of guiguin capsules in the United States.
    Recently, Kangyuan Pharmaceuticals' new class 1 gantry drug WXSH0493 tablets were approved clinically, the data show that WXSH0493 is a highly active, high-safety URT1 inhibitor, clinical positioning is to improve the effectiveness and safety of lesinurad in clinical use, so its market positioning is gnecation and high uric acidemia first-line drug.
    Kangyuan Pharmaceuticals said WXSH0493 will provide new drug options in the clinical treatment of patients with geryro and hypoureticemia, which is expected to address the unsolved clinical needs of these patients and has significant clinical value.
    For the enterprises that have been reviewed and evaluated through the national technology innovation demonstration enterprises, the Ministry of Industry and Information Technology said that it hopes that through the review and evaluation of the enterprises to effectively play the role of demonstration and leadership, continue to improve the system construction, increase investment in technological innovation, strengthen key core technology, and continuously enhance independent innovation capabilities.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.